<DOC>
	<DOCNO>NCT00837837</DOCNO>
	<brief_summary>The purpose study examine pharmacokinetic parameter chlorpheniramine child adolescent .</brief_summary>
	<brief_title>Study Evaluating Chlorpheniramine Maleate Liquid Children Adolescents</brief_title>
	<detailed_description>This single-group , single-center , open-label , one period , bioavailability study . This study evaluate pharmacokinetic ( PK ) profile chlorpheniramine population child age 2 &lt; 12 yr adolescent age 12 &lt; 18 yr . Twelve blood sample ( 3.0 mL ) chlorpheniramine analysis drawn time 0 ( pre-dose ) , 0.5 , 1 , 2 , 3 , 4 , 6 , 8 , 12 , 24 , 48 , 72 hour dose . Plasma level chlorpheniramine determine . The following primary , single-dose PK parameter chlorpheniramine determine use noncompartmental method : AUCL , AUCI , Cmax . The following PK parameter also determine provide complete profile drug , appropriate : oral clearance ( CL ) volume distribution ( Vd ) adjust body weight ( per kg ) ; time reach Cmax ( tmax ) , apparent elimination constant ( Kel ) half-life ( t1/2 ) . The PK parameter summarize use descriptive statistic .</detailed_description>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Chlorpheniramine</mesh_term>
	<criteria>INCLUSION CRITERIA : Individuals may enrol study meet follow criterion : 1 . Males females 2 &lt; 18 yr age minimum weight 24 pound within 5th 95th percentile physical growth characteristic ( i.e. , height weight ) BMI base age gender , 2 . Symptomatic asymptomatic children/adolescents follow : i.A prior diagnosis allergic rhinitis either symptomatic asymptomatic time entry study ; ii.Symptoms acute Upper Respiratory Infection ( URI ) ; iii.No symptom acute URI , risk develop acute URI evidence follow frequency , crowd , exposure criterion : Frequency : history frequent URIs define &gt; 6 infections/yr child age 2 &lt; 6 yr &gt; 4 infection per year adolescent age 6 &lt; 18 yr ; Crowding : living home ≥4 person , sleep bedroom ≥3 person ; Exposure : presence another family member household ill URI , child family attend preschool , attend school ≥6 child class ; c.Except allergic rhinitis URI , children/adolescents normal physical health ( i.e. , clinically significant systemic disease ) judge Investigator upon physical examination subject ; d.Subjects require concomitant medication except lowdose inhaled glucocorticoid allergic rhinitis mild concomitant asthma , dose stabilize entry study ( i.e. , dose change one month prior study ) , inhale shortacting beta2 adrenergic agonist concomitant asthma , need ; e.Post menarchal female must use reliable method contraception ( i.e. , oral , transdermal , injectable implanted contraceptive , IUD , cervical cap , diaphragm , condom , abstinence , surgical sterility ) ; f.Parent/guardian/adolescent provide write informed consent child provide assent , age appropriate . EXCLUSION CRITERIA : Individuals eligible entry study follow note : 1 . The child/adolescent weigh &lt; 24 pound 5th 95th percentile physical growth characteristic ( i.e. , height weight ) BMI base age gender ; 2 . Inability swallow medication ; 3 . Eaten within 2 hour prior dose ; 4 . A known hypersensitivity CHLOR , antihistamine , EMLA® cream ; 5 . Systolic and/or diastolic blood pressure 95th percentile base gender , age height percentile . ( Note : If subject history hypertension blood pressure read 95th percentile , subject allow rest 15 minute blood pressure measurement repeat . Up 3 consecutive measurement approximately 5 min interval allow . Subjects continue systolic and/or diastolic blood pressure read 95th percentile exclude study ) ; 6 . History melena hepatic , renal , endocrine ( e.g. , diabetes , thyroid disorder ) , cardiac , neurological , psychiatric , gastrointestinal , hematological metabolic disorder deem clinically significant Investigator ; 7 . Any serious medical condition medical history felt Investigator place increase risk ; 8 . The child diagnose anemia red blood cell count hemoglobin level outside normal range evidence baseline hematology assessment ; 9 . Asthma symptoms time entry study require medication allow Inclusion Criterion ; 10 . Failure comply appropriate washout period H1 receptor antagonist treatment study , i.e. , use within 7 day enter study time study , use astemizole within precede 3 calendar month ; 11 . Other described Exclusion Criterion , use medication 72 hour prior dose ; 12 . A history drug , alcohol , tobacco abuse ( old child adolescent ) , history Hepatitis B , previous positive test Hepatitis B surface antigen , previous positive Hepatitis C antibody ; 13 . A history HIV infection previous demonstration HIV antibodies ; 14 . Female subject experience menarche positive urine pregnancy test ; 15 . Parent/guardian/subject judged Investigator unable unwilling comply requirement protocol ; 16 . Have take investigational drug within 30 day prior enter study already participate trial ; 17 . Relative Sponsor , Investigator , personnel study site directly involve study .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>pharmacokinetics</keyword>
	<keyword>child</keyword>
	<keyword>adolescent</keyword>
	<keyword>antihistamine</keyword>
</DOC>